Pipeline

EVITA TEST CF

Cystic fibrosis is the most frequent hereditary and life-threatening multiorgan disease in Western Europe. If both parents are healthy carriers of cystic fibrosis, there is a 25% risk of their child having the disease. EVITA TEST CF analyses the fetus’ DNA for the 50 most frequent pathogenic variants of the cystic fibrosis gene. If none of these variants are present, the risk of having a child with cystic fibrosis is extremely small. EVITA TEST CF is the only test on the market that examines both the genes of the pregnant woman and the fetus. EVITA TEST CF can be performed from week 10 – 14.

Newsletter

Subscribe to our newsletter to get the latest updates on products and new scientific publications on ARCEDI technology